MedTrace Logo

Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer

NCT01780701 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 66

Last updated 2017-04-27

No results posted yet for this study

Summary

A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. So, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.

Conditions

Interventions

PROCEDURE

Magnetic Resonance Spectroscopy Imaging with rectal probe

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Portland VA Medical Center

    collaborator FED

  • Oregon Health and Science University

    collaborator OTHER

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Jackilen Shannon, PhD · Oregon Health and Science University

  • Jonathan Q Purnell, MD · Oregon Health and Science University

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2016-01-31
Completion
2017-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01780701 on ClinicalTrials.gov